COMP <GO>
GMED vs UNH // EV/EBITDA & P/E VALUATION
Globus Medical Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GMED 6
— UNH 9
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $78.05 (-5.86%) • MKT CAP: $11.13B
valuation
17.6x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 88.57% | -21.17 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 11.47% | -2.77 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.6x | 16.4x | +1.15 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 6.48% | -1.19 | UNH | /fcf-yield <GO> |
| Operating Margin | 16.30% | 4.82% | +11.48 | GMED | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 3.14% | +15.16 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 6.46% | +10.24 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.74 | 3.12 | +7.62 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 56.0 | -7.02 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.33 | +0.74 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 17.1x | +0.31 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $364.66B | -$353.53B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | UNH REV | GMED GROSS % | UNH GROSS % | GMED FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $447.57B | 67.4% | 88.7% | $588.8M | $16.07B |
| FY 2024 | $2.52B | $400.28B | 58.9% | 88.3% | $405.2M | $20.70B |
| FY 2023 | $1.57B | $371.62B | 44.0% | 89.6% | $172.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
UNH // BETA 0.33